Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Suicide | Research article

Lentivirus-mediated CDglyTK gene-modified free flaps by intra-artery perfusion show targeted therapeutic efficacy in rat model of breast cancer

Authors: Jianhua Zhang, Yuanbo Liu, Mengqing Zang, Shan Zhu, Bo Chen, Shanshan Li, Bingjian Xue, Li Yan

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Free flap-mediated gene therapy in the tumor bed following surgical resection is a promising approach in cancer targeted treatment of residual disease. We investigated the selective killing efficacy of a lentivirus-mediated cytosine deaminase-thymidine kinase (CDglyTK) gene in transplanted breast cancer delivered into a free flap by intra-artery perfusion.

Methods

Proliferation, apoptosis, and cell cycle of rat SHZ-88 breast cancer cells transfected with a lentivirus-mediated CD/TK gene were measured following treatment with ganciclovir and 5-flucytosine in vitro. A model of residual disease of breast cancer in a rat superficial inferior epigastric artery (SIEA) flap model was used to study the therapeutic potential of a double suicide CD/TK and prodrug system in vivo.

Results

Killing efficacy of the double suicide CD/TK and prodrug system on SHZ-88 cells was mediated by increased apoptosis and cell cycle arrest at the G1 phase with significant bystander effect. Following recombinant lentivirus transfection of rat SIEA flap by intra-artery perfusion, CD/TK gene expression was limited to the flap, and the volume and weight of transplanted tumors were significantly reduced without observable toxicity.

Conclusions

SIEA flaps transfected with a lentivirus-mediated CDglyTK gene by intra-artery perfusion effectively suppress transplanted breast tumor growth without obvious systemic toxic effects in rats.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol. 2011;50(2):187–93.CrossRef Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol. 2011;50(2):187–93.CrossRef
2.
go back to reference Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HA. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors. Breast Cancer Res. 2013;15(3):R38.CrossRef Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HA. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors. Breast Cancer Res. 2013;15(3):R38.CrossRef
3.
go back to reference Huang YS, Chen JL, Huang CS, Kuo SH, Jaw FS, Tseng YH, Ko WC, Chang YC. High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study. Breast Cancer Res. 2016;18(1):120.CrossRef Huang YS, Chen JL, Huang CS, Kuo SH, Jaw FS, Tseng YH, Ko WC, Chang YC. High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study. Breast Cancer Res. 2016;18(1):120.CrossRef
4.
go back to reference Mani M, Wang T, Harris P, James S. Breast reconstruction with the deep inferior epigastric perforator flap is a reliable alternative in slim patients. Microsurgery. 2016;36(7):552–8.CrossRef Mani M, Wang T, Harris P, James S. Breast reconstruction with the deep inferior epigastric perforator flap is a reliable alternative in slim patients. Microsurgery. 2016;36(7):552–8.CrossRef
5.
go back to reference Werdin F, Haug DM, Amr A, Schoeller T. Double transverse myocutaneous gracilis free flaps for unilateral breast reconstruction. Microsurgery. 2016;36(7):539–45.CrossRef Werdin F, Haug DM, Amr A, Schoeller T. Double transverse myocutaneous gracilis free flaps for unilateral breast reconstruction. Microsurgery. 2016;36(7):539–45.CrossRef
6.
go back to reference Seth R, Khan AA, Pencavel T, Harrington KJ, Harris PA. Targeted gene delivery by free-tissue transfer in oncoplastic reconstruction. Lancet Oncol. 2012;13(9):e392–402.CrossRef Seth R, Khan AA, Pencavel T, Harrington KJ, Harris PA. Targeted gene delivery by free-tissue transfer in oncoplastic reconstruction. Lancet Oncol. 2012;13(9):e392–402.CrossRef
7.
go back to reference Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46(10):5276–81.PubMed Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46(10):5276–81.PubMed
8.
go back to reference Navarro SA, Carrillo E, Grinan-Lison C, Martin A, Peran M, Marchal JA, Boulaiz H. Cancer suicide gene therapy: a patent review. Expert Opin Ther Patents. 2016;26(9):1095–104.CrossRef Navarro SA, Carrillo E, Grinan-Lison C, Martin A, Peran M, Marchal JA, Boulaiz H. Cancer suicide gene therapy: a patent review. Expert Opin Ther Patents. 2016;26(9):1095–104.CrossRef
9.
go back to reference Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, Fukui H, Ikenaka K, Tsujii T. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology. 1995;22(6):1838–46.PubMed Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, Fukui H, Ikenaka K, Tsujii T. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology. 1995;22(6):1838–46.PubMed
10.
go back to reference Raza A, Kohila V, Ghosh SS. Redesigned Escherichia coli cytosine deaminase: a new facet of suicide gene therapy. J Gene Med. 2015;17(6–7):132–9.CrossRef Raza A, Kohila V, Ghosh SS. Redesigned Escherichia coli cytosine deaminase: a new facet of suicide gene therapy. J Gene Med. 2015;17(6–7):132–9.CrossRef
11.
go back to reference Hashimoto H, Kitano S, Yamagata S, Miyagi Maeshima A, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, et al. Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantation. Cytotherapy. 2015;17(12):1820–30.CrossRef Hashimoto H, Kitano S, Yamagata S, Miyagi Maeshima A, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, et al. Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantation. Cytotherapy. 2015;17(12):1820–30.CrossRef
12.
go back to reference Su GQ, Su G, Huang ZH. Adenovirus-mediated tissue-targeted expression of the CDglyTk gene for the treatment of breast cancer. Mol Med Rep. 2012;6(2):321–9.CrossRef Su GQ, Su G, Huang ZH. Adenovirus-mediated tissue-targeted expression of the CDglyTk gene for the treatment of breast cancer. Mol Med Rep. 2012;6(2):321–9.CrossRef
13.
go back to reference Seth R, Khan AA, Pencavel TD, Wilkinson MJ, Kyula JN, Simpson G, Pandha H, Melcher A, Vile R, Harris PA, et al. Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma. Plast Reconstr Surg. 2015;135(2):475–87.CrossRef Seth R, Khan AA, Pencavel TD, Wilkinson MJ, Kyula JN, Simpson G, Pandha H, Melcher A, Vile R, Harris PA, et al. Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma. Plast Reconstr Surg. 2015;135(2):475–87.CrossRef
14.
go back to reference Li B, Gao N, Zhang Z, Chen QM, Li LJ, Li Y. Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China. Genes. 2017;8(3).CrossRef Li B, Gao N, Zhang Z, Chen QM, Li LJ, Li Y. Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China. Genes. 2017;8(3).CrossRef
15.
go back to reference Petrus I, Chuah M, VandenDriessche T. Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med. 2010;12(10):797–809.CrossRef Petrus I, Chuah M, VandenDriessche T. Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med. 2010;12(10):797–809.CrossRef
16.
go back to reference Wu K, Yang L, Huang Z, Zhao H, Wang J, Xu S. A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells. Oncol Lett. 2016;11(5):3152–60.CrossRef Wu K, Yang L, Huang Z, Zhao H, Wang J, Xu S. A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells. Oncol Lett. 2016;11(5):3152–60.CrossRef
17.
go back to reference Wolff KD, Stiller D. Ischemia tolerance of free-muscle flaps: an NMR-spectroscopic study in the rat. Plast Reconstr Surg. 1993;91(3):485–91.CrossRef Wolff KD, Stiller D. Ischemia tolerance of free-muscle flaps: an NMR-spectroscopic study in the rat. Plast Reconstr Surg. 1993;91(3):485–91.CrossRef
18.
go back to reference Dragu A, Schnurer S, Surmann-Schmitt C, Unglaub F, Kneser U, Horch RE. Expression of HIF-1alpha in ischemia and reperfusion in human microsurgical free muscle tissue transfer. Plast Reconstr Surg. 2011;127(6):2293–300.CrossRef Dragu A, Schnurer S, Surmann-Schmitt C, Unglaub F, Kneser U, Horch RE. Expression of HIF-1alpha in ischemia and reperfusion in human microsurgical free muscle tissue transfer. Plast Reconstr Surg. 2011;127(6):2293–300.CrossRef
19.
go back to reference Leto Barone AA, Zhou ZY, Hughes MW, Park R, Schulman RM, Lee S, Vidar EN, Shiba TL, Weber EL, Cetrulo CL Jr. Lentiviral transduction of face and limb flaps: implications for immunomodulation of vascularized composite allografts. Plast Reconstr Surg. 2012;129(2):391–400.CrossRef Leto Barone AA, Zhou ZY, Hughes MW, Park R, Schulman RM, Lee S, Vidar EN, Shiba TL, Weber EL, Cetrulo CL Jr. Lentiviral transduction of face and limb flaps: implications for immunomodulation of vascularized composite allografts. Plast Reconstr Surg. 2012;129(2):391–400.CrossRef
20.
go back to reference Kobayashi M, Okada T, Murakami T, Ozawa K, Kobayashi E, Morita T. Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems. Urology. 2007;70(6):1230–6.CrossRef Kobayashi M, Okada T, Murakami T, Ozawa K, Kobayashi E, Morita T. Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems. Urology. 2007;70(6):1230–6.CrossRef
21.
go back to reference Michaels J, Levine JP, Hazen A, Ceradini DJ, Galiano RD, Soltanian H, Gurtner GC. Biologic brachytherapy: ex vivo transduction of microvascular beds for efficient, targeted gene therapy. Plast Reconstr Surg. 2006;118(1):54–65 discussion 66-58.CrossRef Michaels J, Levine JP, Hazen A, Ceradini DJ, Galiano RD, Soltanian H, Gurtner GC. Biologic brachytherapy: ex vivo transduction of microvascular beds for efficient, targeted gene therapy. Plast Reconstr Surg. 2006;118(1):54–65 discussion 66-58.CrossRef
22.
go back to reference Sats NV, Shipunova IN, Bigil'diev AE, Drize NI. Stable lentiviral vector transfer into mesenchymal stem cells in vivo. Bull Exp Biol Med. 2015;159(6):764–7.CrossRef Sats NV, Shipunova IN, Bigil'diev AE, Drize NI. Stable lentiviral vector transfer into mesenchymal stem cells in vivo. Bull Exp Biol Med. 2015;159(6):764–7.CrossRef
23.
go back to reference Haid S, Grethe C, Bankwitz D, Grunwald T, Pietschmann T. Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral Pseudotype system. J Virol. 2015;90(6):3065–73.CrossRef Haid S, Grethe C, Bankwitz D, Grunwald T, Pietschmann T. Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral Pseudotype system. J Virol. 2015;90(6):3065–73.CrossRef
24.
go back to reference Niu J, Xing C, Yan C, Liu H, Cui Y, Peng H, Chen Y, Li D, Jiang C, Li N, et al. Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma. Tumour Biol. 2013;34(6):3731–41.CrossRef Niu J, Xing C, Yan C, Liu H, Cui Y, Peng H, Chen Y, Li D, Jiang C, Li N, et al. Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma. Tumour Biol. 2013;34(6):3731–41.CrossRef
25.
go back to reference Liechtenstein T, Perez-Janices N, Bricogne C, Lanna A, Dufait I, Goyvaerts C, Laranga R, Padella A, Arce F, Baratchian M, et al. Immune modulation by genetic modification of dendritic cells with lentiviral vectors. Virus Res. 2013;176(1–2):1–15.CrossRef Liechtenstein T, Perez-Janices N, Bricogne C, Lanna A, Dufait I, Goyvaerts C, Laranga R, Padella A, Arce F, Baratchian M, et al. Immune modulation by genetic modification of dendritic cells with lentiviral vectors. Virus Res. 2013;176(1–2):1–15.CrossRef
26.
go back to reference Li M, Cai H, Yang Y, Zhang J, Sun K, Yan Y, Qu H, Wang W, Wang J, Duan X. Perichondrium mesenchymal stem cells inhibit the growth of breast cancer cells via the DKK-1/Wnt/beta-catenin signaling pathway. Oncol Rep. 2016;36(2):936–44.CrossRef Li M, Cai H, Yang Y, Zhang J, Sun K, Yan Y, Qu H, Wang W, Wang J, Duan X. Perichondrium mesenchymal stem cells inhibit the growth of breast cancer cells via the DKK-1/Wnt/beta-catenin signaling pathway. Oncol Rep. 2016;36(2):936–44.CrossRef
Metadata
Title
Lentivirus-mediated CDglyTK gene-modified free flaps by intra-artery perfusion show targeted therapeutic efficacy in rat model of breast cancer
Authors
Jianhua Zhang
Yuanbo Liu
Mengqing Zang
Shan Zhu
Bo Chen
Shanshan Li
Bingjian Xue
Li Yan
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6111-5

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine